| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 3.7B | +6% |
| Gross Profit | 2.6B | +6% |
| Cost Of Revenue | 1.1B | +4% |
| Operating Income | 584MM | -16% |
| Operating Expenses | 2B | +15% |
| Net Income | 504MM | - |
| R&D | 362MM | +2% |
| G&A | 1.4B | +11% |
| Amortization | 207MM | -0% |
| Interest Expense | 64MM | -3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.
With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.
AHCO vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation (PFA) Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation (AF). The FARAVIEW technology and the FARAWAVE Nav catheter expand the capabilities of the FARAPULSE™ PFA System through integration with our cardiac mapping system.
In this article, we will take a detailed look at the 11 Overvalued Stocks Insiders are Dumping Now. For a quick overview of such stocks, read our article 5 Overvalued Stocks Insiders are Dumping Now. Wise investors almost always keep track of corporate insider activity because paying attention to insider sentiment has proven to be a successful strategy several times […]
Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics. In a regulatory filing, Boston Scientific said Axonics has also received a request for additional information from the FTC and both the companies expect to respond promptly. Boston said it now expects the deal, announced in January, to be completed in the second half of 2024 following the FTC's request, co...
The company has pushed back its expected closing date for the acquisition due to the second request from the Federal Trade Commission.
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2024, on Wednesday, April 24, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 24 prior to the conference call.
Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.
Recently, Scivita Medical Technology Co., Ltd. ("Scivita Medical") and Boston Scientific Corporation (NYSE: BSX), a leading global medical technology company, joined hands again to sign an expanded strategic cooperation arrangement.